NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and BioNTech SE (BNTX) on Tuesday announced the initiation of a clinical trial to evaluate an Omicron-based vaccine candidate in adults 15 to 55 year of age.
The study will have three cohorts examining different regimens of the current Pfizer-BioNTech COVID-19 vaccine or an Omicron-based vaccine, the companies said in a release.
Pfizer And BioNTech further added that first participants enrolled in the study have received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose.
Copyright(c) 2022 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2022 AFX News
